Abstract: The present disclosure provides methods of treating cancer, using multispecific antibodies or antigen-binding fragments thereof that bind to EGFR and CD28 (EGFRxCD28). Such antibodies may be combined with a further therapeutic agent such as an anti-PD-1 antibody, e.g., cemiplimab. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD-1) are also provided.

Abstract: The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody or antigen-binding fragment thereof that specifically binds prostate-specific membrane antigen (PSMA) and CD28 in combination with an antibody or antigen-binding fragment thereof that specifically binds to programmed death receptor-1 (PD-1).